Tag Archives: Alexion

Alexion runs toward big Ultomiris goals with early Soliris switching success

Alexion has big goals for Soliris follow-up Ultomiris in paroxysmal nocturnal hemoglobinuria (PNH), and wooing patients over from predecessor Soliris is key. But so far, executives say, those aims are right on track. As of the end of January—the first full month of the newcomer’s rollout after its Dec. 27 approval—Alexion had switched about 5%… Read More »

With pivot to less-rare diseases, Alexion needs a new sticker-price plan, CEO says

SAN FRANCISCO—In 2019, Alexion is looking to pivot from an ultrarare-disease company to a rare-disease company—and it knows its pricing strategy has to change. With its top-selling therapy, Soliris, the company is moving into new diseases that aren’t nearly as rare as its previous targets. The drug recently nabbed an approval in generalized myasthenia gravis and is looking… Read More »